Aadi Bioscience, Inc. Common Stock
Compare this stock
AADI Stock Report Card
AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.
AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.
AADI has missed earnings 9 times in the last 20 quarters.
Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.
AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.
Aadi Bioscience, Inc. Common Stock Summary
Nasdaq / AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
AADI scored poorly on our reportcard. Here are some similar companies and how they performed.